The rising positron emission tomography (PET) agent 64Cu-SAR-bisPSMA has garnered a quick monitor designation standing from the Meals and Drug Administration (FDA).
Separate part I trials have demonstrated the security and efficacy of 64Cu-SAR-bisPSMA for the imaging of prostate most cancers (PCa) previous to radical prostatectomy and in sufferers with biochemical recurrence of PCa, in response to Readability Prescription drugs, the developer of the PET agent.
Current analysis advised that 64Cu-SAR-bisPSMA has the next detection price than 68Ga PSMA-11 PET/CT for prostate most cancers. At the moment in part III trials, the 64Cu-SAR-bisPSMA PET agent just lately garnered quick monitor designation standing from the Meals and Drug Administration (FDA). (Photos courtesy of the Society of Nuclear Medication and Molecular Imaging (SNMMI)).
In comparative analysis offered on the 2023 Society of Nuclear Medication and Molecular Imaging (SNMMI) convention, researchers discovered that 64Cu-SAR-bisPSMA had the next detection price for PCa and the next median tumor-to-background ratio (TBR) compared to 68Ga PSMA-11 PET/CT. Readability Prescription drugs famous that present part III trials are ongoing for 64Cu-SAR-bisPSMA.
“We imagine that 64Cu-SAR-bisPSMA could possibly be a sport changer in prostate most cancers analysis. Resulting from its twin concentrating on construction, bisPSMA, and the longer half-life of copper-64, enabling next-day imaging, this distinctive product has proven increased tumor uptake and retention and exhibited a functionality of detecting a lot smaller lesions,” famous Alan Taylor, the chief chairperson for Readability Prescription drugs.
